Abstract |
11 patients with refractory acute leukemia of childhood were treated with idarubicin per os. Bone marrow toxicity which was observed at a dose level of 60 mg/m2 p.o. (3 x 20 mg q 24 hrs p.o.) per 3 weeks was found to be the dose limiting factor. In contrast to the first phase I study of Tan et al. (16) the maximal tolerated dose in the present study was found to be lower at a level of 90 mg/m2 p.o. (3 x 30 mg/m2 p.o. q 24 hrs) per 3 weeks. Therefore, we recommend a dosage of 60 mg/m2 p.o. (3 x 20 mg/m2 p.o. q 24 hrs) per 3 weeks as a starting dose for phase II/III studies. 2 out of the 11 anthracycline pretreated patients (91-880 mg/m2) with acute leukemia reached a complete remission undergoing idarubicin p.o. as a single therapy.
|
Authors | R Erttmann, U Bode, N Erb, P Forcadell de Dios, P Gutjahr, R Haas, N Kuhn, H Siewert, G Landbeck |
Journal | Klinische Padiatrie
(Klin Padiatr)
1988 May-Jun
Vol. 200
Issue 3
Pg. 200-4
ISSN: 0300-8630 [Print] Germany |
Vernacular Title | Antineoplastische Wirksamkeit und Toxizität von Idarubicin (4-Demethoxydaunorubicin) bei rezidivierten akuten Leukämien des Kindesalters. |
PMID | 3062256
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Idarubicin
|
Topics |
- Adolescent
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Bone Marrow
(drug effects)
- Child
- Child, Preschool
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Idarubicin
(adverse effects, therapeutic use)
- Leukemia, Lymphoid
(drug therapy)
- Leukemia, Myeloid, Acute
(drug therapy)
- Leukocyte Count
(drug effects)
- Male
- Remission Induction
|